Investment report on Spectrum Pharmaceuticals

May 3 2010

MicroStockProfit.com announces an investment report featuring Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/SPPI

Spectrum Pharmaceuticals Inc. (SPPI) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company's product is apaziquone (formerly EOquin), which is in two phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix, is in a phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Ltd., Spectrum Pharmaceuticals GmbH, RIT Oncology LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

Message Board Search for SPPI: http://www.boardcentral.com/boards/SPPI

In the report, the analyst notes:

"Consolidated revenue of $8.6 million was comprised of product sales of $5.2 million - $5.1 million from ZEVALIN, an increase of 8.5% over third quarter 2009, and $0.1 million from FUSILEV - $1.5 million attributable to the milestone payment upon full enrollment of the apaziquone phase 3 trials, and $1.9 million attributable to the amortization of the Allergan licensing fee.

"SPPI recently announced results of a pre-clinical study conducted by the National Cancer Institute of belinostat in the treatment of small-cell lung cancer that was presented in a poster session on Wednesday, April 21, 2010, at the 101st Annual Meeting of the American Association for Cancer Research (AACR), being held at the Walter E. Washington Convention Center in Washington, DC."